1. Search Result
Search Result
Results for "

INS-1

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

3

Natural
Products

4

Recombinant Proteins

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103642A

    Inositol 1,4,5-trisphosphate trisodium; INS(1,4,5)-P3 trisodium

    Others Metabolic Disease
    D-myo-Inositol-1,4,5-triphosphate sodium salt is the trisodium salt of D-myo-Inositol 1,4,5-trisphosphate (1,4,5-IP3), which is a second messenger that stimulates the discharge of calcium from the endoplasmic reticulum.
    D-myo-Inositol-1,4,5-triphosphate trisodium
  • HY-150135B

    Inositol 1,4,5-trisphosphate tripotassium; INS(1,4,5)-P3 tripotassium

    Calcium Channel Neurological Disease
    D-myo-Inositol 1,4,5-trisphosphate tripotassium, a second messenger, elicits Ca 2+ mobilization. D-myo-Inositol 1,4,5-trisphosphate tripotassium inhibits the binding of phosphoinositide-specific phospholipase C-delta 1 (PLC-delta 1) to bilayer membranes composed of phosphatidylcholine (PC) and phosphatidylinositol 4,5-bisphosphate (PIP2) [1].
    D-myo-Inositol 1,4,5-trisphosphate tripotassium
  • HY-13529
    Globalagliatin
    1 Publications Verification

    LY2608204

    Glucokinase Metabolic Disease
    Globalagliatin (LY2608204) is an orally active glucokinase (GK) activator with an EC50 of 42 nM. Globalagliatin also stimulates glucose metabolism in rat insulinoma INS1-E cells with EC50 of 579 nM. Globalagliatin targets both pancreatic β-cells and hepatocytes. Globalagliatin is promising for research of type 2 diabetes [1] .
    Globalagliatin
  • HY-N0668
    Rubusoside
    2 Publications Verification

    GLUT Amylases NF-κB Metabolic Disease Inflammation/Immunology Cancer
    Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase) [1] .
    Rubusoside
  • HY-148001

    Phosphatase Dopamine β-hydroxylase Others
    EWP 815 is a disulfiram analogue, is a potent inhibitor of Ins(1,4)P2 phosphatase and Ins(1,4,5)P3 5-phosphatase. EWP 815 also inhibits enzyme dopamine β-hydroxylase activity [1] .
    EWP 815
  • HY-126750
    GNF362
    1 Publications Verification

    Phosphatase Inflammation/Immunology
    GNF362 is a selective, potent, and orally bioavailable inhibitor of inositol trisphosphate 3’ kinase B (Itpkb) with an IC50 of 9 nM. GNF362 also inhibits Itpka and Itpkc with IC50 values of 20 nM and 19 nM, respectively. Inositol trisphosphate 3’ kinase B (Itpkb) is a Ca 2+-dependent kinase, which phosphorylates the 3’ position of Ins (1,4,5) P3 to generate inositol 1,3,4,5-tetrakisphosphate [Ins (1,3,4,5) P4] [1].
    GNF362
  • HY-50722
    NNC 55-0396
    4 Publications Verification

    NNC 55-0396 dihydrochloride

    Calcium Channel Cardiovascular Disease Neurological Disease
    NNC 55-0396 is a highly selective T-type calcium channel blocker with an IC50 value of 6.8 μM for Cav3.1 T-type channels. NNC 55-0396 can be used for the research of neurological disease research [1] .
    NNC 55-0396
  • HY-103642

    Inositol 1,4,5-trisphosphate hexapotassium salt; INS(1,4,5)-P3 hexapotassium salt

    Others Metabolic Disease
    D-myo-Inositol 1,4,5-trisphosphate hexapotassium salt is the hexapotassium salt of D-myo-Inositol 1,4,5-trisphosphate (1,4,5-IP3), which is a second messenger that stimulates the discharge of calcium from the endoplasmic reticulum.
    D-myo-Inositol 1,4,5-trisphosphate hexapotassium salt
  • HY-145422

    IRE1 Apoptosis Others
    KIRA9 is a potent IRE1 inhibitor (IC50=4.8 μM in INS-1 cells). KIRA9 is able to fully engage the ATP-binding site of IRE1α. KIRA9 can block ER-localized mRNA decay and apoptosis [1].
    KIRA9
  • HY-N0668R

    GLUT Amylases NF-κB Metabolic Disease Inflammation/Immunology Cancer
    Rubusoside (Standard) is the analytical standard of Rubusoside. This product is intended for research and analytical applications. Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase) [1] .
    Rubusoside (Standard)
  • HY-44153

    Potassium Channel Neurological Disease
    KV2 channel inhibitor-1 is a selective KV2 channel inhibitor with IC50s of 0.2 μM and 0.41 μM for KV2.1 and KV2.2, respectively. KV2 channel inhibitor-1 possesses good selectivity over KV1.2 (IC50>10 μM). KV2 channel inhibitor-1 is >10-fold selective over NaV channels and other KV channels and displays weak activity on CaV channels [1].
    KV2 channel inhibitor-1
  • HY-123245

    TRP Channel Phospholipase ERK Akt Inflammation/Immunology Cancer
    Scalaradial is an inhibitor for bee venom phospholipase A2 (PLA2) and transient receptor potential melastatin 2 (TRPM2) ion channels, with IC50 of 0.07 and 0.21 μM. Scalaradial regulates the phosphorylation of ERK, by inhibiting secretory PLA2 and Akt. Scalaradial inhibits the PMA (HY-18739)-induced release of Arachidonic acid (HY-109590) in the mouse peritoneal macrophage [1] .
    Scalaradial
  • HY-146455

    Dipeptidyl Peptidase Reactive Oxygen Species Metabolic Disease
    DPP-4-IN-3 (Compound 5a) is a potent dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 0.75 nM. DPP-4-IN-3 shows excellent antioxidant and insulinotropic activity [1].
    DPP-4-IN-3
  • HY-120962

    TRP Channel Metabolic Disease
    N-Arachidonoyl Taurine is an activator of the transient receptor potential vanilloid TRPV1 and TRPV4, with EC50s value of 28 μM and 21 μM, respectively [1].
    N-Arachidonoyl Taurine
  • HY-145418

    IRE1 Others
    IRE1α kinase-IN-3 (compound 2) is a potent IRE1α inhibitor with an Ki of 480 nM. IRE1α kinase-IN-3 is the ATP-competitive ligands of IRE1α [1].
    IRE1α kinase-IN-3
  • HY-145419

    IRE1 Others
    IRE1α kinase-IN-4 (compound 6) is a potent IRE1α inhibitor with an Ki of 140 nM. IRE1α kinase-IN-4 is the ATP-competitive ligands of IRE1α [1].
    IRE1α kinase-IN-4
  • HY-145420

    IRE1 Others
    IRE1α kinase-IN-5 (compound 7) is a potent IRE1α inhibitor with an Ki of 98 nM. IRE1α kinase-IN-5 is the ATP-competitive ligands of IRE1α [1].
    IRE1α kinase-IN-5
  • HY-115403
    FKGK18
    1 Publications Verification

    Phospholipase Apoptosis Metabolic Disease
    FKGK18 is a selective group VIA calcium-independent phospholipase A2 (GVIA iPLA2) inhibitor. FKGK18 is a fluoroketone (FK)-based compound with IC50s of 50 nM and 3 μM for iPLA2β and iPLA2γ. FKGK18 can be used for the research of beta-cell apoptosis and diabetes [1] .
    FKGK18
  • HY-153347
    JY-2
    1 Publications Verification

    FOXO Metabolic Disease
    JY-2 is a moderately selective and orally active Forkhead transcription factor forkhead box O1 (FoxO1) inhibitor that inhibits FoxO1 transcriptional activity with an IC50 of 22 μM. JY-2 shows moderate inhibition against FoxO3a and FoxO4. JY-2 shows anti-diabetic activity [1].
    JY-2
  • HY-137640B

    PKA Inflammation/Immunology Cancer
    Rp-8-Br-cAMPS is an analog of cAMP and an inhibitor of PKA. Rp-8-Br-cAMPS occupies cAMP binding sites on PKA type I regulatory subunits, thereby preventing PKA dissociation and activation. Rp-8-Br-cAMPS can be used in the study of tumors and retrovirus-induced immune deficiency. Rp-8-Br-cAMPS also inhibits insulin secretion [1] .
    Rp-8-Br-cAMPS
  • HY-137640C

    PKA Inflammation/Immunology Cancer
    Rp-8-Br-cAMPS sodium is an analog of cAMP and an inhibitor of PKA. Rp-8-Br-cAMPS sodium occupies cAMP binding sites on PKA type I regulatory subunits, thereby preventing PKA dissociation and activation. Rp-8-Br-cAMPS sodium can be used in the study of tumors and retrovirus-induced immune deficiency. Rp-8-Br-cAMPS sodium also inhibits insulin secretion [1] .
    Rp-8-Br-cAMPS sodium
  • HY-15671

    Glucokinase Metabolic Disease
    GKA50 is a potent glucokinase activator (EC50=33 nM at 5 mM glucose). GKA50 stimulates insulin release from mouse islets of Langerhans. GKA50 is a glucose-like activator of beta-cell metabolism in rodent and human islets and a Ca 2+-dependent modulator of insulin secretion. GKA50 shows significant glucose lowering in high fat fed female rats [1] .
    GKA50
  • HY-15671A

    Glucokinase Metabolic Disease
    GKA50 quarterhydrate is a potent glucokinase activator (EC50=33 nM at 5 mM glucose) and stimulates insulin release from mouse islets of Langerhans. GKA50 quarterhydrate is a glucose-like activator of beta-cell metabolism in rodent and human islets and a Ca 2+-dependent modulator of insulin secretion. GKA50 quarterhydrate shows significant glucose lowering in high fat fed female rats [1] .
    GKA50 quarterhydrate
  • HY-142114

    Others Metabolic Disease
    SRI-37330 is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. SRI-37330 inhibits glucagon secretion and function, reduces hepatic glucose production and reverses hepatic steatosis. SRI-37330 can be used for type 2 diabetes research [1].
    SRI-37330
  • HY-151257

    Hippo (MST) Metabolic Disease
    IHMT-MST1-58 is a potent, selective mammalian and orally active STE20-like protein 1 kinase (MST1) inhibitor with IC50 value of 23 nM. IHMT-MST1-58 can be used for the research of Type 1/2 diabetes [1].
    IHMT-MST1-58

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: